While soluble ACE2 functional as both lung-protecting enzyme and decoy for SARS-CoV-2 might be good for COVID-19 treatment, the ACE2 enzymatic activity of B38-CAP is likely sufficient for treating ARDS induced by other causes. This evidence concerns the gene ACE2 and acute respiratory distress syndrome.